LON:SHP - Shire Stock Price, Price Target & More

GBX 3,821.50 -153.50 (-3.86 %)
(As of 04/22/2018 02:51 AM ET)
Previous CloseGBX 3,821.50
Today's RangeGBX 3,744 - GBX 3,946
52-Week RangeGBX 2,940.50 - GBX 5,021
Volume12.16 million shs
Average Volume3.14 million shs
Market Capitalization£29.14 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Shire (LON:SHP)

Shire logoShire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells specialist medicines for people with rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. The company's marketed products also comprise VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR and MYDAYIS to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of CINRYZE and FIRAZYR for the treatment of hereditary angioedema; FOSRENOL to treat hyperphosphatemia; LIALDA/MEZAVANT and PENTASA for ulcerative colitis; GATTEX/REVESTIVE for the treatment of short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA for the treatment of dry eye disease. The company markets its products through wholesalers, distributors, and pharmacies. It has collaborative and other licensing arrangements with Rani Therapeutics LLC; Parion Sciences Inc.; Pfizer Inc.; Precision BioSciences Inc.; Symphogen; and Ipsen Bioscience Inc. The company was founded in 1986 and is headquartered in Dublin, Ireland.

Receive SHP News and Ratings via Email

Sign-up to receive the latest news and ratings for SHP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolLON:SHP
CUSIPN/A
Phone+353-1-6096000

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins16.73%
Return on Equity8.11%
Return on Assets4.11%

Miscellaneous

EmployeesN/A
Outstanding Shares908,640,000

How to Become a New Pot Stock Millionaire

Shire (LON:SHP) Frequently Asked Questions

What is Shire's stock symbol?

Shire trades on the London Stock Exchange (LON) under the ticker symbol "SHP."

How often does Shire pay dividends? What is the dividend yield for Shire?

Shire declared a dividend on Wednesday, February 14th. Stockholders of record on Thursday, March 8th will be given a dividend of GBX 21.46 per share on Tuesday, April 24th. This represents a dividend yield of 0.67%. The ex-dividend date of this dividend is Thursday, March 8th. This is a boost from Shire's previous dividend of $3.85. The official announcement can be viewed at this link. View Shire's Dividend History.

What price target have analysts set for SHP?

20 analysts have issued 1 year target prices for Shire's shares. Their predictions range from GBX 3,559 to GBX 8,000. On average, they expect Shire's share price to reach GBX 4,573.30 in the next twelve months. View Analyst Ratings for Shire.

Who are some of Shire's key competitors?

Who are Shire's key executives?

Shire's management team includes the folowing people:
  • Dr. Flemming Ornskov M.P.H., MBA, M.D., MPH, CEO, MD & Exec. Director (Age 60)
  • Mr. Thomas J. W. Dittrich, CFO & Director (Age 54)
  • Gisele Dion, Chief Accounting Officer
  • Mr. Matthew Walker, Head of Technical Operations (Age 54)
  • Prof. Andreas Busch Ph.D., Head of R&D, Chief Scientific Officer & Exec. VP (Age 55)

Has Shire been receiving favorable news coverage?

Press coverage about SHP stock has been trending somewhat positive this week, Accern reports. The research firm identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Shire earned a daily sentiment score of 0.20 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 45.85 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

How do I buy shares of Shire?

Shares of SHP and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Shire's stock price today?

One share of SHP stock can currently be purchased for approximately GBX 3,821.50.

How big of a company is Shire?

Shire has a market capitalization of £29.14 billion.

How can I contact Shire?

Shire's mailing address is Miesian Plaza 50-58 Baggot Street Lower, Block 2, DUBLIN, D02 HW68, Ireland. The biopharmaceutical company can be reached via phone at +353-1-6096000.


MarketBeat Community Rating for Shire (SHP)

Community Ranking:  4.1 out of 5 (star star star star)
Outperform Votes:  1,234 (Vote Outperform)
Underperform Votes:  288 (Vote Underperform)
Total Votes:  1,522
MarketBeat's community ratings are surveys of what our community members think about Shire and other stocks. Vote "Outperform" if you believe SHP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SHP will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Shire (LON:SHP) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
20 Wall Street analysts have issued ratings and price targets for Shire in the last 12 months. Their average twelve-month price target is GBX 4,573.30The high price target for SHP is GBX 8,000 and the low price target for SHP is GBX 3,559. There are currently 4 hold ratings, 15 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.852.822.822.89
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
15 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
12 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
12 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
14 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: GBX 4,573.30GBX 4,950GBX 5,146.88GBX 5,893.18

Shire (LON:SHP) Consensus Price Target History

Price Target History for Shire (LON:SHP)

Shire (LON:SHP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
4/20/2018CfraSet Price TargetBuyGBX 4,500View Rating Details
4/17/2018Deutsche BankReiterated RatingBuyGBX 3,559View Rating Details
4/17/2018Royal Bank of CanadaReiterated RatingOutperformView Rating Details
4/16/2018Shore CapitalReiterated RatingBuyGBX 3,607View Rating Details
4/16/2018Liberum CapitalReiterated RatingHoldGBX 4,000View Rating Details
4/9/2018BNP ParibasReiterated RatingOutperformGBX 4,700View Rating Details
4/4/2018Societe GeneraleSet Price TargetBuyGBX 7,500View Rating Details
4/3/2018Sanford C. BernsteinSet Price TargetBuyGBX 4,400View Rating Details
3/29/2018Kepler Capital MarketsReiterated RatingBuyGBX 4,250View Rating Details
3/29/2018HSBCReiterated RatingHoldView Rating Details
3/28/2018Main First BankInitiated CoverageOutperformGBX 3,600View Rating Details
3/28/2018Jefferies GroupReiterated RatingBuyGBX 4,100View Rating Details
3/27/2018Morgan StanleyReiterated RatingOverweightGBX 4,700View Rating Details
3/26/2018Goldman SachsReiterated RatingConviction-BuyGBX 4,600View Rating Details
3/20/2018Credit Suisse GroupReiterated RatingOutperformGBX 4,000View Rating Details
2/23/2018Berenberg BankLower Price TargetBuyGBX 6,000 -> GBX 4,500View Rating Details
2/21/2018CitigroupReiterated RatingBuyGBX 5,500View Rating Details
2/20/2018JPMorgan ChaseDowngradeNeutralGBX 5,000 -> GBX 3,600View Rating Details
2/15/2018BarclaysReiterated RatingEqual weightGBX 3,650View Rating Details
1/29/2018InvestecReiterated RatingBuyGBX 8,000View Rating Details
8/4/2017Beaufort SecuritiesReiterated RatingLong Term BuyGBX 6,200 -> GBX 4,900View Rating Details
2/16/2017UBSReiterated RatingNeutralGBX 5,000View Rating Details
1/9/2017Bryan, Garnier & CoReiterated RatingBuyGBX 6,800View Rating Details
11/7/2016AlphaValueReiterated RatingBuyGBX 6,714View Rating Details
11/3/2016Bank of AmericaReiterated RatingBuyGBX 6,970View Rating Details
(Data available from 4/22/2016 forward)

Earnings

Dividends

Shire (LON:SHP) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/14/2018GBX 21.460.67%3/8/20183/8/20184/24/2018
8/3/2017GBX 3.850.1%9/7/20179/7/201710/20/2017
2/16/2017GBX 20.640.43%3/9/20173/9/20174/25/2017
8/2/2016GBX 3.510.07%9/8/20169/8/201610/7/2016
2/11/2016GBX 15.320.44%3/10/20163/10/20164/12/2016
7/23/2015GBX 2.690.05%9/3/20159/3/201510/2/2015
7/18/2014GBX 2.240.04%9/3/20149/3/201410/3/2014
2/13/2014GBX 10.210.31%3/5/20143/5/20144/8/2014
(Data available from 1/1/2013 forward)

Insider Trades

Shire (LON SHP) Insider Trading and Institutional Ownership History

Insider Trading History for Shire (LON:SHP)

Shire (LON SHP) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/14/2018Mark Clayton JarvisDirectorSell365,000GBX 0.06£219
12/19/2017Dominic BlakemoreInsiderBuy165GBX 3,790£6,253.50
9/29/2017Anne MintoInsiderBuy190GBX 3,785£7,191.50
8/22/2017Flemming OrnskovInsiderBuy8,400GBX 3,665£307,860
6/30/2017Dominic BlakemoreInsiderBuy152GBX 4,255£6,467.60
3/31/2017William BurnsInsiderBuy136GBX 4,742£6,449.12
12/16/2016Olivier BohuonInsiderBuy141GBX 4,528£6,384.48
9/30/2016Dominic BlakemoreInsiderBuy133GBX 5,010£6,663.30
6/30/2016Bohuon,OlivierInsiderBuy134GBX 4,463£5,980.42
3/31/2016Bohuon,OlivierInsiderBuy133GBX 3,908£5,197.64
2/15/2016Bohuon,OlivierInsiderBuy1,000GBX 3,552£35,520
2/12/2016Burns,WilliamInsiderBuy1,250GBX 3,563£44,537.50
12/18/2015Burns,WilliamInsiderBuy156GBX 4,457£6,952.92
9/30/2015Blakemore ,DominicInsiderBuy129GBX 4,498£5,802.42
6/30/2015Kappler,David JInsiderBuy126GBX 51.05GBX 6,432.30
3/31/2015Susan KilsbyInsiderBuy375GBX 5,327£19,976.25
12/19/2014Steven GillisInsiderBuy228GBX 4,654£10,611.12
10/30/2014Steven GillisInsiderBuy381GBX 4,098£15,613.38
(Data available from 1/1/2013 forward)

Headlines

Shire (LON SHP) News Headlines

Source:
DateHeadline
Shire (SHP) Rating Reiterated by Liberum CapitalShire (SHP) Rating Reiterated by Liberum Capital
www.americanbankingnews.com - April 20 at 6:56 PM
Shire (SHP) Rating Reiterated by Shore CapitalShire (SHP) Rating Reiterated by Shore Capital
www.americanbankingnews.com - April 20 at 6:54 PM
Shires (SHP) "Buy" Rating Reaffirmed at Deutsche BankShire's (SHP) "Buy" Rating Reaffirmed at Deutsche Bank
www.americanbankingnews.com - April 20 at 5:18 PM
Shire (SHP) Earns "Overweight" Rating from JPMorgan ChaseShire (SHP) Earns "Overweight" Rating from JPMorgan Chase
www.americanbankingnews.com - April 20 at 5:18 PM
Shire Pandemonium, Aluminum Glut, ZTE Fallout: CEO Daily for April 20, 2018Shire Pandemonium, Aluminum Glut, ZTE Fallout: CEO Daily for April 20, 2018
fortune.com - April 20 at 5:15 PM
Takeda increases bid for ShireTakeda increases bid for Shire
www.cnbc.com - April 20 at 5:15 PM
Takeda sweetens offer for rival Shire to £42.8bnTakeda sweetens offer for rival Shire to £42.8bn
www.ft.com - April 20 at 5:15 PM
Shire (SHP) Rating Reiterated by BarclaysShire (SHP) Rating Reiterated by Barclays
www.americanbankingnews.com - April 20 at 4:48 PM
Shire (SHP) Earns "Outperform" Rating from Credit Suisse GroupShire (SHP) Earns "Outperform" Rating from Credit Suisse Group
www.americanbankingnews.com - April 20 at 4:48 PM
Royal Bank of Canada Reiterates Outperform Rating for Shire (SHP)Royal Bank of Canada Reiterates Outperform Rating for Shire (SHP)
www.americanbankingnews.com - April 20 at 4:16 PM
Cfra Reiterates "GBX 4,500" Price Target for Shire (SHP)Cfra Reiterates "GBX 4,500" Price Target for Shire (SHP)
www.americanbankingnews.com - April 20 at 11:55 AM
Shire (SHP) Receives "Hold" Rating from Liberum CapitalShire (SHP) Receives "Hold" Rating from Liberum Capital
www.americanbankingnews.com - April 19 at 7:36 PM
JPMorgan Chase Reaffirms "Overweight" Rating for Shire (SHP)JPMorgan Chase Reaffirms "Overweight" Rating for Shire (SHP)
www.americanbankingnews.com - April 19 at 6:22 PM
Shire, commodity stocks lift FTSE to 10-week highShire, commodity stocks lift FTSE to 10-week high
www.nasdaq.com - April 19 at 5:31 PM
Shire Rejects Takedas Takeover BidShire Rejects Takeda's Takeover Bid
www.bloomberg.com - April 19 at 5:31 PM
Shire plc : Statement re Proposal from Takeda Pharmaceutical Company LimitedShire plc : Statement re Proposal from Takeda Pharmaceutical Company Limited
globenewswire.com - April 19 at 5:31 PM
UPDATED: Rare Disease Drug Maker Shires Stock Spikes Amid Possible Bidding War Between Allergan and TakedaUPDATED: Rare Disease Drug Maker Shire's Stock Spikes Amid Possible Bidding War Between Allergan and Takeda
fortune.com - April 19 at 5:31 PM
Allergan Bows Out Of Shire Battle Against Takeda After Stock SlammedAllergan Bows Out Of Shire Battle Against Takeda After Stock Slammed
finance.yahoo.com - April 19 at 5:31 PM
Takeda in talks with Shire after 46.50 stg/shr bid rejectedTakeda in talks with Shire after 46.50 stg/shr bid rejected
finance.yahoo.com - April 19 at 8:24 AM
Shires (SHP) Buy Rating Reiterated at Societe GeneraleShire's (SHP) Buy Rating Reiterated at Societe Generale
www.americanbankingnews.com - April 18 at 10:48 PM
Form 8-K Shire plc For: Apr 18Form 8-K Shire plc For: Apr 18
www.streetinsider.com - April 18 at 5:38 PM
Shire plc : Notice of ResultsShire plc : Notice of Results
finance.yahoo.com - April 18 at 5:38 PM
Jazz Pharmaceuticals’ Xyrem, Erwinase, and DefitelioJazz Pharmaceuticals’ Xyrem, Erwinase, and Defitelio
finance.yahoo.com - April 18 at 5:38 PM
FDA expands approval of Shire blood-clotting drugFDA expands approval of Shire blood-clotting drug
www.marketwatch.com - April 17 at 5:47 PM
BRIEF-Shire Says FDA Approves Vonvendi For Perioperative Management Of Bleeding In Adult Patients With Von ...BRIEF-Shire Says FDA Approves Vonvendi For Perioperative Management Of Bleeding In Adult Patients With Von ...
www.reuters.com - April 17 at 5:47 PM
Shire (SHP) Stock Rating Reaffirmed by Shore CapitalShire (SHP) Stock Rating Reaffirmed by Shore Capital
www.americanbankingnews.com - April 17 at 11:37 AM
Deutsche Bank Reaffirms "Buy" Rating for Shire (SHP)Deutsche Bank Reaffirms "Buy" Rating for Shire (SHP)
www.americanbankingnews.com - April 17 at 8:07 AM
Shires (SHP) "Outperform" Rating Reiterated at Royal Bank of CanadaShire's (SHP) "Outperform" Rating Reiterated at Royal Bank of Canada
www.americanbankingnews.com - April 17 at 6:47 AM
Shire sells cancer drugs to Servier as Takeda circlesShire sells cancer drugs to Servier as Takeda circles
www.reuters.com - April 16 at 5:14 PM
Shire (SHP) Earns Buy Rating from Shore CapitalShire (SHP) Earns Buy Rating from Shore Capital
www.americanbankingnews.com - April 16 at 7:11 AM
Liberum Capital Reaffirms "Hold" Rating for Shire (SHP)Liberum Capital Reaffirms "Hold" Rating for Shire (SHP)
www.americanbankingnews.com - April 16 at 7:11 AM
Takeda boss to meet US investors ahead of potential £35bn Shire bidTakeda boss to meet US investors ahead of potential £35bn Shire bid
uk.finance.yahoo.com - April 15 at 6:29 PM
Liberum Capital Reiterates "Hold" Rating for Shire (SHP)Liberum Capital Reiterates "Hold" Rating for Shire (SHP)
www.americanbankingnews.com - April 13 at 6:01 PM
Credit Suisse Group Reiterates Outperform Rating for Shire (SHP)Credit Suisse Group Reiterates Outperform Rating for Shire (SHP)
www.americanbankingnews.com - April 13 at 1:03 PM
Shire (SHP) Given "Overweight" Rating at JPMorgan ChaseShire (SHP) Given "Overweight" Rating at JPMorgan Chase
www.americanbankingnews.com - April 13 at 1:00 PM
Shire (SHP) Receives "Buy" Rating from Deutsche BankShire (SHP) Receives "Buy" Rating from Deutsche Bank
www.americanbankingnews.com - April 13 at 12:25 PM
Beaufort Securities Reaffirms Long Term Buy Rating for Shire (SHP)Beaufort Securities Reaffirms Long Term Buy Rating for Shire (SHP)
www.americanbankingnews.com - April 13 at 10:53 AM
Shires (SHP) Buy Rating Reaffirmed at Berenberg BankShire's (SHP) Buy Rating Reaffirmed at Berenberg Bank
www.americanbankingnews.com - April 11 at 10:42 PM
Shire (SHP) Downgraded to "Equal weight" at BarclaysShire (SHP) Downgraded to "Equal weight" at Barclays
www.americanbankingnews.com - April 10 at 7:17 PM
Liberum Capital Cuts Shire (SHP) Price Target to GBX 4,400Liberum Capital Cuts Shire (SHP) Price Target to GBX 4,400
www.americanbankingnews.com - April 10 at 6:40 PM
Is Takedas Rumored Buyout of Shire Smart?Is Takeda's Rumored Buyout of Shire Smart?
www.fool.com - April 10 at 5:23 PM
Shire (SHPG) is in Overbought Territory: Whats Next?Shire (SHPG) is in Overbought Territory: What's Next?
www.nasdaq.com - April 10 at 5:23 PM
Shires (SHP) Buy Rating Reiterated at Shore CapitalShire's (SHP) Buy Rating Reiterated at Shore Capital
www.americanbankingnews.com - April 10 at 1:10 PM
Shire (SHP) Stock Rating Reaffirmed by Credit Suisse GroupShire (SHP) Stock Rating Reaffirmed by Credit Suisse Group
www.americanbankingnews.com - April 10 at 8:37 AM
Shire (SHP) Rating Reiterated by Jefferies GroupShire (SHP) Rating Reiterated by Jefferies Group
www.americanbankingnews.com - April 10 at 8:37 AM
Shires (SHP) "Buy" Rating Reiterated at CitigroupShire's (SHP) "Buy" Rating Reiterated at Citigroup
www.americanbankingnews.com - April 10 at 8:36 AM
Cantor Fitzgerald Remains Bullish on Shire (SHPG)Cantor Fitzgerald Remains Bullish on Shire (SHPG)
www.streetinsider.com - April 9 at 5:13 PM
Deutsche Bank Trims Shire (SHP) Target Price to GBX 5,700Deutsche Bank Trims Shire (SHP) Target Price to GBX 5,700
www.americanbankingnews.com - April 9 at 2:58 PM
BNP Paribas Reiterates "Outperform" Rating for Shire (SHP)BNP Paribas Reiterates "Outperform" Rating for Shire (SHP)
www.americanbankingnews.com - April 9 at 6:03 AM
Shires (SHP) "Hold" Rating Reiterated at Liberum CapitalShire's (SHP) "Hold" Rating Reiterated at Liberum Capital
www.americanbankingnews.com - April 8 at 9:07 AM

SEC Filings

Shire (LON:SHP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

Shire (LON SHP) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.